AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25310928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 146
Study 25310928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 23064870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (HYP)
Number of subjects: 32
Study 23064870 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EUH)
Number of subjects: 32
Study 23064870 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 10 °C
Number of subjects: 32
Study 19502599 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of vitamin A
Number of subjects: 576
Study 19502599 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vitamin A levels
Number of subjects: 576
Study 18695765 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine co-administered with rotavirus vaccine
Number of subjects: 2464
Study 18695765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study 15041394 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 50 mg (two doses on day 0 and day 14)
Number of subjects: 54
Study 15041394 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 25 mg (two doses on day 0 and day 14)
Number of subjects: 54
Study 15041394 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg (two doses on day 0 and day 4)
Number of subjects: 54
Study 15041394 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction
Number of subjects: 54
Study 12511059 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced methadone treatment primarily cognitive‐behavioral therapy (CBT) for cocaine use
Number of subjects: 0
Study 12511059 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 0
Study 9821596 — intervention group
Group type: EXPERIMENTAL
Intervention: Swanson prostheses
Number of subjects: 72
Study 9821596 — intervention group
Group type: COMPARATOR
Intervention: Sutter prostheses
Number of subjects: 72
Study 9821596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 7545060 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 1362
Study 7545060 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 1362
Study 7545060 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 1362
Study 2571308 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 0
Study 2571308 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 0
Study 2571308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1172753 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% potassium chloride solution
Number of subjects: 20
Study 1172753 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy-matrix potassium chloride tablet
Number of subjects: 20
Study 30242918 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 850
Study 30242918 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 850
Study 30242918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 27873502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urapidil
Number of subjects: 180
Study 27873502 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 180
Study 25927360 — intervention group
Group type: EXPERIMENTAL
Intervention: JAIVAC-1 (10 μg, 25 μg, and 50 μg of each antigen)
Number of subjects: 45
Study 25927360 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (standard dosage)
Number of subjects: 45
Study 23100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford chair group
Number of subjects: 60
Study 23100318 — intervention group
Group type: COMPARATOR
Intervention: Traditional method group
Number of subjects: 60
Study 21781475 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ± 5 mg/kg salt iodization
Number of subjects: 3
Study 21781475 — intervention group
Group type: COMPARATOR
Intervention: 35 ± 5 mg/kg salt iodization
Number of subjects: 3
Study 21781475 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume measurement
Number of subjects: 3
Study 19259615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 150
Study 19259615 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 150
Study 16952155 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN1
Number of subjects: 0
Study 16952155 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV cellular changes
Number of subjects: 0
Study 15248939 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandage (4LB)
Number of subjects: 387
Study 15248939 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch bandage (SSB)
Number of subjects: 387
Study 11736779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1 microg x kg(‐1) intra‐operatively
Number of subjects: 60
Study 11736779 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 100 microg x kg(‐1) at induction
Number of subjects: 60
Study 11736779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 9416883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 965
Study 8107618 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone administered by nasal spray (34 mg daily for 5-7 days) with oral estrogens for 3-4 weeks
Number of subjects: 10
Study 8107618 — intervention group
Group type: COMPARATOR
Intervention: Progesterone administered by nasal spray (34 mg daily for 6 days) without estrogens
Number of subjects: 10
Study 3632375 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (45 mg/kg)
Number of subjects: 32
Study 3632375 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 32
Study 3632375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31221949 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 45
Study 31221949 — intervention group
Group type: COMPARATOR
Intervention: Placebo ESWT
Number of subjects: 45
Study 29698021 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Low (4% ABV for wine, 1% ABV for beer)
Number of subjects: 264
Study 29698021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (8% ABV for wine, 3% ABV for beer)
Number of subjects: 264
Study 29698021 — intervention group
Group type: COMPARATOR
Intervention: Regular (no verbal descriptors of strength)
Number of subjects: 264
Study 27019334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (psychosocial program tailored to prevent depression)
Number of subjects: 3326
Study 27019334 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 3326
Study 24115373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-FS adropin concentrations
Number of subjects: 0
Study 24115373 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-FS adropin concentrations
Number of subjects: 0
Study 24115373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-FS adropin concentrations (kcal adjusted for body size)
Number of subjects: 0
Study 22859794 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 185
Study 22859794 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solutions
Number of subjects: 185
Study 20523212 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 60
Study 20523212 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 60
Study 18787222 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (intravenous loading dose, 2 mg/kg, then 1 mg/kg) every 2 weeks, added to stable-dose TAA through Week 12.
Number of subjects: 115
Study 18787222 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks, added to stable-dose TAA through Week 12.
Number of subjects: 115
Study 15116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco Lilliput 1 Oxygenator with 750 mL priming volume
Number of subjects: 40
Study 15116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Minimax Oxygenator
Number of subjects: 40
Study 15116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco Lilliput 1 Oxygenator with 450 mL priming volume
Number of subjects: 40
Study 11339517 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 599
Study 11339517 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 599
Study 11339517 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 599
Study 9039945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1500 IU of anti‐HBs)
Number of subjects: 12
Study 9039945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular immunoglobulin (1000 IU of anti‐HBs)
Number of subjects: 12
Study 9039945 — intervention group
Group type: COMPARATOR
Intervention: Switch from intravenous to intramuscular immunoglobulin
Number of subjects: 12
Study 7951343 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g dipyrone
Number of subjects: 104
Study 7951343 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tramadol
Number of subjects: 104
Study 7951343 — intervention group
Group type: COMPARATOR
Intervention: 20 mg butylscopolamine
Number of subjects: 104
Study 7951343 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 104
Study 3306163 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20 mg every 6 hours)
Number of subjects: 123
Study 3306163 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg followed by 0.25 mg daily)
Number of subjects: 123
Study 3306163 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 123
Study 28574274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 28574274 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 28574274 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition strategies from intravenous to oral P2Y12 receptor antagonists
Number of subjects: 0
Study 29414986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced water levels in troughs
Number of subjects: 35
Study 29414986 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal water levels)
Number of subjects: 35
Study 27714002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling with currants (two fruit servings, 36 g per day)
Number of subjects: 55
Study 27714002 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling (Control arm)
Number of subjects: 55
Study 24856557 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine (SAMe) 1600-3200mg/daily
Number of subjects: 144
Study 24856557 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20mg/daily
Number of subjects: 144
Study 24856557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 22156333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV patient-controlled analgesia (PCA)
Number of subjects: 80
Study 22156333 — intervention group
Group type: COMPARATOR
Intervention: Conventional IV nurse‐administered as‐needed (PRN) therapy
Number of subjects: 80
Study 20477775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 60
Study 20477775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17404000 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily for 5 days)
Number of subjects: 92
Study 17404000 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 5 days)
Number of subjects: 92
Study 16376202 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb aerobic exercise training (UL-Ex)
Number of subjects: 104
Study 16376202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-limb aerobic exercise training (LL-Ex)
Number of subjects: 104
Study 16376202 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise training control group
Number of subjects: 104
Study 12555509 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg od)
Number of subjects: 200
Study 12555509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg od)
Number of subjects: 200
Study 12555509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 200
Study 9430987 — intervention group
Group type: EXPERIMENTAL
Intervention: AAACa (200 mg calcium)
Number of subjects: 8
Study 9430987 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (200 ml after breakfast, supper, and at bedtime)
Number of subjects: 8
Study 9430987 — intervention group
Group type: COMPARATOR
Intervention: Control (no calcium supplement)
Number of subjects: 8
Study 8007703 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR (Fenretinide)
Number of subjects: 2972
Study 8007703 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year administration of 4-HPR
Number of subjects: 2972
Study 8007703 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR
Number of subjects: 2972
Study 2831594 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with a non-specific adjuvant
Number of subjects: 219
Study 31566800 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first analgesic medication
Number of subjects: 727
Study 31566800 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department length of stay (ED LOS)
Number of subjects: 727
Study 28581323 — intervention group
Group type: EXPERIMENTAL
Intervention: Givers practiced 5 acts of kindness for a personalized list of Receivers over 4 weeks
Number of subjects: 111
Study 28581323 — intervention group
Group type: EXPERIMENTAL
Intervention: Receivers of kindness from Givers
Number of subjects: 111
Study 28581323 — intervention group
Group type: EXPERIMENTAL
Intervention: Givers' prosocial acts
Number of subjects: 111
Study 28581323 — intervention group
Group type: COMPARATOR
Intervention: Controls (no specific intervention mentioned)
Number of subjects: 111
Study 26674366 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 26674366 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008
Study 26674366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 26093189 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based screening strategy (age <= 25, multiple sexual partners, inconsistent condom use, history of prior STI)
Number of subjects: 5087
Study 26093189 — intervention group
Group type: COMPARATOR
Intervention: Age-based screening (age <= 25)
Number of subjects: 5087
Study 26093189 — intervention group
Group type: COMPARATOR
Intervention: Age/partner-based screening (age <= 25 and/or multiple sexual partners)
Number of subjects: 5087
Study 26093189 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based screening strategy
Number of subjects: 5087
Study 23846486 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (400 mg or 800 mg of total EGCG daily, administered in split doses)
Number of subjects: 20
Study 23846486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23846486 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 20
Study 21831559 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational referral condition (MRC)
Number of subjects: 113
Study 21831559 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC plus incentive (MRC + I)
Number of subjects: 113
Study 21831559 — intervention group
Group type: COMPARATOR
Intervention: Standard referral condition
Number of subjects: 113
Study 18419948 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg intravenous injection based on psychological nursing intervention
Number of subjects: 87
Study 18419948 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 87
Study 18419948 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 87
Study 17137979 — intervention group
Group type: EXPERIMENTAL
Intervention: On-axis clear corneal incision (CCI)
Number of subjects: 62
Study 17137979 — intervention group
Group type: COMPARATOR
Intervention: Temporal clear corneal incision (CCI)
Number of subjects: 62
Study 12662955 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 0
Study 12662955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10685585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia and low-intensity exercise
Number of subjects: 6
Study 9506266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin prophylaxis
Number of subjects: 0
Study 8352874 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based Primary Care Curriculum (PCC) track
Number of subjects: 675
Study 8352874 — intervention group
Group type: COMPARATOR
Intervention: Conventional track
Number of subjects: 675
Study 8352874 — intervention group
Group type: COMPARATOR
Intervention: High-risk students in the conventional track
Number of subjects: 675
Study 31695534 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Number of subjects: 13
Study 31695534 — intervention group
Group type: COMPARATOR
Intervention: Placebo cocktail
Number of subjects: 13
Study 29735468 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection 150mg (Group B)
Number of subjects: 0
Study 29735468 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection 200mg (Group C)
Number of subjects: 0
Study 29735468 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen axetil injection 100mg (Group A)
Number of subjects: 0
Study 26999730 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced intervention (group B)
Number of subjects: 2379
Study 26999730 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (group A)
Number of subjects: 2379
Study 24283249 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation assessment of spinal posture, active movements of the lumbar spine, and the SLR test
Number of subjects: 26
Study 24283249 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face physical therapist assessment
Number of subjects: 26
Study 21347523 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance exercise training protocol (n = 27)
Number of subjects: 52
Study 21347523 — intervention group
Group type: COMPARATOR
Intervention: Standardized therapeutic exercise protocol (n = 25)
Number of subjects: 52
Study 21347523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve sparing neck dissection procedures
Number of subjects: 52
Study 20305847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 74
Study 20305847 — intervention group
Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 74
Study 20305847 — intervention group
Group type: EXPERIMENTAL
Intervention: New complete dentures
Number of subjects: 74
Study 20305847 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of edentulism
Number of subjects: 74
Study 17448631 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42
Study 17448631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15788975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Angiography (RA)
Number of subjects: 31
Study 15788975 — intervention group
Group type: COMPARATOR
Intervention: Traditional Angiography (TA)
Number of subjects: 31
Study 12871780 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum syndecan‐1 level (>212 microg/l)
Number of subjects: 88
Study 12871780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum syndecan‐1 level (≤212 microg/l)
Number of subjects: 88
Study 10329064 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 20536
Study 10329064 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily)
Number of subjects: 20536
Study 10329064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo tablets for simvastatin)
Number of subjects: 20536
Study 10329064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo capsules for vitamins)
Number of subjects: 20536
Study 10329064 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 20536
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-unplanned cesarean birth (n = 122)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with diabetes (n = 55)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy (n = 109)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low birthweight (VLBW) infants (n = 79)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly with medical cardiac DRGs (n = 142)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly with surgical cardiac DRGs (n = 134)
Number of subjects: 764
Study 8936246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean and infants, hysterectomy and surgical elderly groups
Number of subjects: 764
Study 1929608 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (Indo) 150 mg administered intravenously on days 0 to 5
Number of subjects: 60
Study 1929608 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) administered subcutaneously on days 0, 2, 4, and Indomethacin
Number of subjects: 60
Study 1929608 — intervention group
Group type: COMPARATOR
Intervention: Control group (PC)
Number of subjects: 60
Study 6753893 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 207
Study 6753893 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg three times a day
Number of subjects: 207